The share

The shares of Inify Laboratories AB are listed on Euronext Growth Oslo since June 20th, 2022. All shares have equal rights and are freely transferable. Please follow the development of the Inify Laboratories share on Euronext Growth and view stock exchange releases at NewsWeb.
Euronext Growth
NewsWeb

Share information

Ticker code
Number of shares
Trading currency
Sector
ISIN
LEI code
INIFY
107,474,845
NOK
Health care
SE0017486103
549300306YYJ3BX3VB98

Shareholders

The shares of Inify Laboratories AB are listed on Euronext Growth Oslo under the ticker INIFY.
The list of total shares and the 20 largest shareholders is updated monthly, usually at month end. The last update was made on April 15th, 2026. The company has a total of 107,474,845 outstanding shares.
Euronext Growth

20 largest shareholders

Number of shares heldOwnership (%)Shareholder
64 578 36160,09%Gallivant S.á.r.l.
12 803 51111,91%TAURI AS
12 289 88811,44%MONSUN AS
3 556 1463,31%BRAS KAPITAL AS
3 278 6133,05%Danske Bank A/S
2 676 2182,49%Günther-Hanssen, Sven
1 382 2431,29%MP PENSJON PK
999 5880,93%Avanza Bank AB, MEGLERKONTO
742 3890,69%OLSEN, LARS EJNAR
432 0370,40%SKJELBRED, RUNE
425 8000,40%STAVLAND, PER
410 4060,38%Danske Bank A/S
399 0150,37%Skandinaviska Enskilda Banken AB
325 3560,30%SVEEN, KRISTIAN
267 6500,25%Nordnet Bank AB
200 0000,19%SANDVIK, RUNE
162 3110,15%OLE KRISTIAN AS
136 2100,13%STORHAUGEN INVEST AS
121 9740,11%MYHRA, GUNNAR
120 1560,11%Swedbank AB
2 166 9732,02%Others
107 474 845100,00%Total

Primary Insider Transactions

Information about primary insider transactions can be found under Investor news.

Dividend policy

The board of Inify Laboratories AB has not adopted a dividend policy since the Company considers itself to be in a growth phase, and therefore does not foresee that it will pay dividends in the near future. In deciding whether to propose a dividend and in determining the dividend amount, the Board of Directors will take into account legal restrictions as well as capital expenditure plans, financing requirements and maintaining the appropriate strategic flexibility.